These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21418179)

  • 1. Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment.
    Teichert M; van Noord C; Uitterlinden AG; Hofman A; Buhre PN; De Smet PA; Straus S; Stricker BH; Visser LE
    Br J Haematol; 2011 May; 153(3):379-85. PubMed ID: 21418179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.
    Gschwind L; Rollason V; Boehlen F; Rebsamen M; Combescure C; Grünenwald M; Matthey A; Bonnabry P; Dayer P; Desmeules JA
    Pharmacogenomics; 2013 May; 14(7):745-53. PubMed ID: 23651023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acenocoumarol stabilization is delayed in CYP2C93 carriers.
    Schalekamp T; van Geest-Daalderop JH; de Vries-Goldschmeding H; Conemans J; Bernsen Mj Mj; de Boer A
    Clin Pharmacol Ther; 2004 May; 75(5):394-402. PubMed ID: 15116052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.
    Verhoef TI; Redekop WK; Buikema MM; Schalekamp T; Van Der Meer FJ; Le Cessie S; Wessels JA; Van Schie RM; De Boer A; Teichert M; Visser LE; Maitland-Van Der Zee AH;
    J Thromb Haemost; 2012 Apr; 10(4):606-14. PubMed ID: 22252093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants.
    Visser LE; Penning-van Beest FJ; Kasbergen AA; De Smet PA; Vulto AG; Hofman A; Stricker BH
    Clin Pharmacol Ther; 2002 Jun; 71(6):496-502. PubMed ID: 12087353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective serotonin re-uptake inhibiting antidepressants and the risk of overanticoagulation during acenocoumarol maintenance treatment.
    Teichert M; Visser LE; Uitterlinden AG; Hofman A; Buhre PJ; Straus S; De Smet PA; Stricker BH
    Br J Clin Pharmacol; 2011 Nov; 72(5):798-805. PubMed ID: 21545482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?
    Schalekamp T; Boink GJ; Visser LE; Stricker BH; de Boer A; Klungel OH
    Clin Pharmacol Ther; 2006 Jun; 79(6):511-20. PubMed ID: 16765138
    [No Abstract]   [Full Text] [Related]  

  • 8. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.
    Visser LE; Penning-van Bees FJ; Kasbergen AA; De Smet PA; Vulto AG; Hofman A; Stricker BH
    Thromb Haemost; 2002 Nov; 88(5):705-10. PubMed ID: 12428081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.
    van Schie RM; Babajeff AM; Schalekamp T; Wessels JA; le Cessie S; de Boer A; van der Meer FJ; van Meegen E; Verhoef TI; Rosendaal FR; Maitland-van der Zee AH;
    J Thromb Haemost; 2012 May; 10(5):767-72. PubMed ID: 22409277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon.
    Becker ML; Franken WP; Karapinar F; Verzijl-Zeegers R; Schalekamp T; van der Hoeven RT
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1461-5. PubMed ID: 26400679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Thromb Haemost; 2004 Jul; 92(1):61-6. PubMed ID: 15213846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
    Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
    Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.
    André-Kerneïs E; Leroy-Matheron C; Gouault-Heilmann M
    Blood Coagul Fibrinolysis; 2003 Dec; 14(8):761-4. PubMed ID: 14614357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.
    Schalekamp T; Brassé BP; Roijers JF; Chahid Y; van Geest-Daalderop JH; de Vries-Goldschmeding H; van Wijk EM; Egberts AC; de Boer A
    Clin Pharmacol Ther; 2006 Jul; 80(1):13-22. PubMed ID: 16815313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.
    Verstuyft C; Morin S; Robert A; Loriot MA; Beaune P; Jaillon P; Becquemont L
    Pharmacogenetics; 2001 Nov; 11(8):735-7. PubMed ID: 11692083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs.
    Penning-van Beest FJ; van Meegen E; Rosendaal FR; Stricker BH
    Clin Pharmacol Ther; 2001 Jun; 69(6):451-7. PubMed ID: 11406743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
    Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
    Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
    Hsiao FY; Mullins CD; Wen YW; Huang WF; Chen PF; Tsai YW
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1043-9. PubMed ID: 21823195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
    Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
    Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.
    Teichert M; van Schaik RH; Hofman A; Uitterlinden AG; de Smet PA; Stricker BH; Visser LE
    Clin Pharmacol Ther; 2009 Apr; 85(4):379-86. PubMed ID: 19225451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.